Fluoroquinolones: Difference between revisions
No edit summary |
|||
| Line 13: | Line 13: | ||
**Hyper/hypoglycemia | **Hyper/hypoglycemia | ||
**Hematologic toxicity | **Hematologic toxicity | ||
**depression/suicidality | |||
*Black box warning from US FDA | *Black box warning from US FDA | ||
*Tendon Rupture & Tendinitis <ref>Gültuna S. et al. Ciprofloxacin induced tendinitis. J Clin Rheumatol. 2009;15 (4): 201-2</ref> | **Tendon Rupture & Tendinitis <ref>Gültuna S. et al. Ciprofloxacin induced tendinitis. J Clin Rheumatol. 2009;15 (4): 201-2</ref> | ||
*Peripheral Neuropathy<ref>Food and Drug Administration: Drug safety announcement about fluoroquinolones and possible peripheral neuropathy [http://www.fda.gov/downloads/Drugs/DrugSafety/UCM365078.pdf PDF]</ref> | **Peripheral Neuropathy<ref>Food and Drug Administration: Drug safety announcement about fluoroquinolones and possible peripheral neuropathy [http://www.fda.gov/downloads/Drugs/DrugSafety/UCM365078.pdf PDF]</ref> | ||
Revision as of 20:41, 22 October 2018
Indications
- UTI (2nd line)
- Prostatitis
- Chlamydia
- PID
- Traveler's Diarrhea
Adverse Effects
- Common adverse effects
- GI and neuro toxicity
- Rash
- QT prolongation
- Hyper/hypoglycemia
- Hematologic toxicity
- depression/suicidality
- Black box warning from US FDA
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
See Also
References
- Goodman & Gilman's Pharmacology
- FDA info for Health Professionals